Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsored by: |
Department of Veterans Affairs |
---|---|
Information provided by: | Department of Veterans Affairs |
ClinicalTrials.gov Identifier: | NCT00108537 |
The primary objective of this study is to determine which is the better approach to smoking cessation in veterans: bupropion combined with transdermal nicotine or high dose nicotine replacement therapy (NRT) using transdermal nicotine combined with nicotine inhaler.
Condition | Intervention | Phase |
---|---|---|
Tobacco Use Disorder |
Drug: bupropion and transdermal patch Drug: transdermal patch and nicotine inhaler |
Phase III |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Open Label, Uncontrolled |
Official Title: | Non-Nicotine Agents for Smoking Cessation |
Study Start Date: | October 2003 |
Estimated Study Completion Date: | September 2005 |
This study is a two-arm open-label, randomized controlled trial of bupropion combined with transdermal nicotine versus high dose NRT (transdermal nicotine and nicotine inhaler) with all subjects receiving a behavioral counseling program for smoking cessation.
Ages Eligible for Study: | 18 Years to 65 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Study ID Numbers: | ADRD-013-01S |
Study First Received: | April 15, 2005 |
Last Updated: | April 2, 2008 |
ClinicalTrials.gov Identifier: | NCT00108537 |
Health Authority: | United States: Federal Government |
smoking nicotine drug therapy smoking cessation |
Nicotine polacrilex Smoking Nicotine Mental Disorders |
Tobacco Use Disorder Bupropion Substance-Related Disorders Disorders of Environmental Origin |
Neurotransmitter Agents Cholinergic Agonists Molecular Mechanisms of Pharmacological Action Nicotinic Agonists Physiological Effects of Drugs Central Nervous System Stimulants Cholinergic Agents |
Pharmacologic Actions Autonomic Agents Therapeutic Uses Ganglionic Stimulants Peripheral Nervous System Agents Central Nervous System Agents |